Information Provided By:
Fly News Breaks for April 13, 2016
JAZZ
Apr 13, 2016 | 08:22 EDT
Leerink analyst Jason Gerberry believes the Patent Trial and Appeal Board, or PTAB, ruling declining to institute 18 claims in the '306 Xyrem patent validates his thesis that 2016 legal events will de-risk near and medium-term Jazz Pharmaceuticals' Xyrem generic risk and provide the company with additional leverage to structure value enhancing settlements with the patent challengers. The analyst reiterates an Outperform rating and a $167 price target on the shares.
News For JAZZ From the Last 2 Days
There are no results for your query JAZZ